Cargando…
Treatment response to Janus kinase inhibitor in a child affected by Aicardi‐Goutières syndrome
KEY CLINICAL MESSAGE: Baricitinib, a Janus kinase inhibitor (JAK‐inhibitor), seems to contribute to an improvement of a child affected by Aicardi‐Goutières syndrome (AGS), reducing the interferon score and determining a recovery of cognitive, communicative, and relational dysfunctions, while the gro...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390657/ https://www.ncbi.nlm.nih.gov/pubmed/37534202 http://dx.doi.org/10.1002/ccr3.7724 |